By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Ventana is developing a companion diagnostic test for an oncology drug developed by Seattle Genetics and Millennium Pharmaceuticals under a deal announced today.

The companion diagnostic being developed by Ventana, a Roche company, will be for identifying patients who best respond to Adcetris (brentuximab vedotin) based on CD30 expression levels in their tissue specimens. Under the terms of the agreement, Ventana will develop, manufacture, and commercialize the test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.